In pre­emp­tive strike, Sanders, Cum­mings de­mand PTC chief Peltz spell out his price for con­tro­ver­sial Duchenne MD treat­ment

It’s time for Stu­art Peltz to take the Con­gres­sion­al hot seat on drug pric­ing.

The CEO of PTC Ther­a­peu­tics ac­quired Marathon’s steroid de­flaza­cort for $140 mil­lion up front a few days ago with an eye to sell it to a small pop­u­la­tion of Duchenne mus­cu­lar dy­s­tro­phy pa­tients. And that comes with as much of a glar­ing spot­light as Sen­a­tor Bernie Sanders and Rep. Eli­jah Cum­mings can bring to it.

In a new let­ter di­rect­ed to Peltz, the two ac­tivist law­mak­ers not­ed in a pre­emp­tive strike that the CEO has been in touch with the Par­ent Project for Mus­cu­lar Dy­s­tro­phy to talk price. And they have a re­tail num­ber in mind that PTC $PTCT won’t like­ly cot­ton to: The UK net price of $1,000 to $1,200 a month, which is what many par­ents are pay­ing to­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.